Acumen said sabirnetug (ACU193), a monoclonal antibody designed to selectively target toxic amyloid beta oligomers, remains in a fully enrolled global Phase 2 intravenous study in early Alzheimer’s disease, with topline results expected in late 2026. The company also cited an Enhanced Brain Delivery program combining a TfR brain transporter with an anti-amyloid beta oligomer antibody, with an IND targeted for mid-2027. Acumen reported cash, cash equivalents and marketable securities of USD 136 million as of Sept. 30, 2025, and said it expects its cash runway to extend into early 2027. It also referenced Phase 1 data for sabirnetug in early Alzheimer’s patients that included 5 total cases of ARIA-E, or about 10%. A related Phase 1 study is cited as INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.